Insulin products are grouped by how quickly they start working (onset), when they work hardest (peak), and how long the effect lasts (duration). This matters practically because rapid- and short-acting insulins are timed around meals, while intermediate-, long-, and ultra-long-acting insulins are timed to give steady, background ("basal") coverage. Note that exact timings vary somewhat between patients and are affected by dose size, injection site, and individual physiology — the ranges below are typical estimates, not exact promises.
~1 week per dose
Insulin icodec
Not currently available in Nepal. Approved and launched in the US, EU, Canada, Japan, Australia, China, and India (2025–2026); not yet reported as launched or formally announced for the Nepali market as of mid-2026
1. Rapid-acting (bolus/mealtime) insulin — insulin aspart, lispro, and glulisine are modified ("analog") insulins engineered to be absorbed faster than regular human insulin. They start working in about 10 to 20 minutes, peak around an hour, and last 3 to 5 hours, so they are usually injected just before or right at the start of a meal to match the glucose rise from food. NovoRapid (aspart) and Humalog (lispro) are both available in Nepal, generally at a higher price than regular human insulin.
2. Short-acting / Regular insulin — unmodified human insulin, absorbed more slowly than the rapid-acting analogs. It needs to be injected 30 minutes before a meal to work in time, peaks in 2 to 4 hours, and lasts 5 to 8 hours. This is the classic, oldest form of mealtime insulin and remains very widely used in Nepal (Actrapid, Huminsulin R, Insugen R) mainly because of its significantly lower cost compared with rapid-acting analogs.
3. Intermediate-acting (NPH) insulin — a modified human insulin (isophane, NPH) with protamine added to slow its absorption, giving a broader, less predictable peak (4 to 12 hours) and a duration of 12 to 18 hours. It is typically given once or twice daily to provide background coverage. It is cloudy in appearance (unlike clear rapid/short-acting insulin) and must be gently rolled, not shaken, before use. NPH (Insulatard, Huminsulin N, Insugen N) is widely available and affordable in Nepal and remains a mainstay basal option, especially where cost is a major concern.
4. Premixed insulin — a fixed-ratio combination of a rapid- or short-acting insulin with an intermediate-acting (NPH) insulin in the same pen or vial (e.g., 70% NPH/30% regular, or 75/25, 50/50 with analogs). This gives one injection that covers both background and mealtime needs, which is convenient and reduces the number of daily injections — a major reason premixed insulin (Mixtard 30/70, Novomix 30, Humalog Mix 25/50) is extremely commonly prescribed in Nepal. The trade-off is less flexibility to adjust the mealtime and basal components separately, and a more pronounced, dual-peak action profile that requires more careful meal timing to avoid hypoglycemia.
5. Long-acting insulin — glargine and detemir are modified insulins designed to be absorbed slowly and steadily over roughly 20 to 24 hours, with little to no pronounced peak, making them useful for once-daily (sometimes twice-daily for detemir) basal coverage with a lower hypoglycemia risk than NPH. Glargine (Lantus, and biosimilar versions such as Basalog and Glaritus) is available in Nepal and increasingly prescribed where affordability allows; detemir (Levemir) is less commonly stocked.
6. Ultra-long-acting insulin — insulin degludec is engineered for an even flatter, more prolonged action profile, lasting well beyond 24 hours (commonly cited as up to 42 or more hours), which gives more flexibility in dosing time and a lower nighttime hypoglycemia risk compared with glargine or NPH. Degludec (Tresiba) is available in Nepal through larger pharmacies and hospital pharmacies, but at a noticeably higher price than NPH or standard glargine, which limits its use mainly to patients who can afford it or where hypoglycemia risk specifically warrants it.
7. Once-weekly insulin — insulin icodec is a newly developed basal insulin engineered with strong, reversible binding to albumin in the blood, giving it a half-life of roughly eight days and allowing a single injection to provide steady basal coverage for a full week — reducing yearly basal injections from 365 to about 52. It reaches steady, stable activity after three to four weekly doses and has shown glucose control similar to or better than daily glargine in large clinical trials, currently approved for type 2 diabetes (not yet approved for type 1 diabetes). As of mid-2026, insulin icodec (brand name Awiqli) has been approved and launched in the US, European Union, Canada, Japan, Australia, China, and India, among roughly a dozen additional markets. It has not been reported as launched or formally announced in Nepal at this time. Given that it has already reached the Indian market — Nepal's largest and most closely linked pharmaceutical supply source — it is reasonable to expect that it could become available in Nepal in the coming years, but this is an expectation based on regional pharmaceutical trends rather than any confirmed plan, and should be checked against current Department of Drug Administration (DDA) Nepal registrations before being presented to patients as imminent.
In Nepal, the choice between these insulin types is often driven as much by affordability as by clinical preference. Regular human insulin, NPH, and premixed human insulins remain the most widely used and least expensive options and are entirely appropriate, effective therapy for most patients. Newer analog insulins (rapid-acting analogs, glargine, degludec) offer real clinical advantages — more predictable action, lower hypoglycemia risk, more flexible timing — but at a meaningfully higher cost, which matters for long-term affordability and adherence. This is a reasonable, non-judgmental conversation to have with patients: cost-appropriate insulin, taken consistently, is far better than an "ideal" insulin that is skipped due to price.
This article has been published by the Healthnep editorial team for general information and educational purposes only. The author is not a licensed medical doctor or professional healthcare practitioner. The content provided here does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified health provider regarding any medical condition or before starting any new treatment. Never disregard professional medical advice or delay seeking it because of something you have read on this platform.
यो लेख MedPortal सम्पादकीय टोलीद्वारा सामान्य जानकारी र शैक्षिक उद्देश्यका लागि मात्र प्रकाशित गरिएको हो। लेखक इजाजतपत्र प्राप्त चिकित्सक वा पेशेवर स्वास्थ्य व्यवसायी होइनन्। कुनै पनि स्वास्थ्य समस्याको लागि आफ्नो चिकित्सकसँग परामर्श गर्नुहोस्।
Common name in Nepal (Glimepiride, Gliclazide, and Glipizide)What Are Sulfonylureas?Sulfon...
Read MoreWhat Are SGLT2 Inhibitors?SGLT2 इनहिबिटर के हो?SGLT2 inhibitors ar...
Read More